Am J Obstet Gynecol:先兆子痫孕妇:布洛芬vs对乙酰氨基酚对产后高血压有何影响?

2018-06-29 王淳 环球医学

2018年1月,发表在《Am J Obstet Gynecol》的一项由美国学者进行的双盲、随机、对照试验,比较了布洛芬vs对乙酰氨基酚对具有严重特征的先兆子痫患者产后高血压的影响。

2018年1月,发表在《Am J Obstet Gynecol》的一项由美国学者进行的双盲、随机、对照试验,比较了布洛芬vs对乙酰氨基酚对具有严重特征的先兆子痫患者产后高血压的影响。

背景:已有研究表明非甾体抗炎药(NSAID)的使用可增加非妊娠成年人的血压。正因如此,美国妇产科医师学会建议产后高血压女性避免使用NSAIDs类药物,然而,缺乏支持该建议的临床证据。

目的:旨在检验假设,即NSAID如布洛芬,对具有严重特征的先兆子痫女性的产后血压控制具有不利影响。

研究设计:分娩后,研究人员将具有严重特征的先兆子痫女性随机分配到每6小时连续口服布洛芬600mg或对乙酰氨基酚650mg组中。分娩后6小时内开始给药,并持续到出院,按需给予阿片类镇痛药治疗爆发痛。

研究药物密封在完全相同的胶囊中,以便对患者、护士和医生设盲。排除标准为ALT或AST>200mg/dL,SCr>1.0mg/dL,传染性肝炎,胃食管返流征,小于18岁,监禁中。首要结局为严重范围高血压的持续时间,其定义为自分娩到末次检测血压≥160/110mmHg的时间(以小时计算)。次要结局为自分娩到末次检测血压≥150/100mmHg的时间、平均动脉压、出院时需要抗高血压药、因血压控制不佳延长住院、产后使用短效降压药进行急性血压控制、使用阿片类药物治疗爆发痛。根据意向治疗原则,研究人员分析了所有结局数据。

结果:154名进行评估的女性中100名符合入组标准,并同意参加试验,将其随机分配到产后布洛芬或对乙酰氨基酚进行一线疼痛控制组中。7名患者交叉使用或未接受分配的研究药物,93人在各自的分组中完成研究程序。

组间基线特征无差异,包括分娩方式、BMI、之前妊娠情况、民族、慢性高血压和分娩前的最高血压。布洛芬vs对乙酰氨基酚组严重范围高血压持续时间无差异(35.3 vs 38.0小时,P=0.30)。两组在自分娩到末次检测血压≥150/100mmHg的时间、产后平均动脉压、产后最高收缩压或舒张压、任何产后血压≥160/110mmHg、产后使用短效降压药进行急性血压控制、产后住院日、因血压控制不佳延长住院、出院时需要抗高血压药、使用阿片类药物进行充分的疼痛控制等次要结局测量上无差异。

在严重范围高血压患者的亚组分析中,对乙酰氨基酚和布洛芬组血压控制的平均时间分别为68.4和56.7小时(P=0.26)。产后6周时,两组在产科就诊率、再住院率、继续使用阿片类药物或继续使用抗高血压药上无差异。

结论:在具有严重特征的先兆子痫女性中,一线使用布洛芬而非对乙酰氨基酚进行产后疼痛控制并不会延长严重范围高血压的持续时间。

原始出处:

Blue NR, Murray-Krezan C, Drake-Lavelle S, et al. Effect of ibuprofen vs acetaminophen on postpartum hypertension in preeclampsia with severe features: a double-masked, randomized controlled trial. Am J Obstet Gynecol. 2018 Jun;218(6):616.e1-616.e8. doi: 10.1016/j.ajog.2018.02.016. Epub 2018 Mar 2.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2044054, encodeId=a7eb2044054bb, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Dec 21 02:45:00 CST 2018, time=2018-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952064, encodeId=a6c919520643f, content=<a href='/topic/show?id=3dbb2346632' target=_blank style='color:#2F92EE;'>#乙酰氨基酚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23466, encryptionId=3dbb2346632, topicName=乙酰氨基酚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Mon Oct 08 21:45:00 CST 2018, time=2018-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011380, encodeId=6e40201138030, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Thu Aug 23 20:45:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321789, encodeId=a5e51321e8925, content=<a href='/topic/show?id=818246618a4' target=_blank style='color:#2F92EE;'>#对乙酰氨基酚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46618, encryptionId=818246618a4, topicName=对乙酰氨基酚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afdf491, createdName=lilili1104, createdTime=Sun Jul 01 02:45:00 CST 2018, time=2018-07-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2044054, encodeId=a7eb2044054bb, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Dec 21 02:45:00 CST 2018, time=2018-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952064, encodeId=a6c919520643f, content=<a href='/topic/show?id=3dbb2346632' target=_blank style='color:#2F92EE;'>#乙酰氨基酚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23466, encryptionId=3dbb2346632, topicName=乙酰氨基酚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Mon Oct 08 21:45:00 CST 2018, time=2018-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011380, encodeId=6e40201138030, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Thu Aug 23 20:45:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321789, encodeId=a5e51321e8925, content=<a href='/topic/show?id=818246618a4' target=_blank style='color:#2F92EE;'>#对乙酰氨基酚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46618, encryptionId=818246618a4, topicName=对乙酰氨基酚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afdf491, createdName=lilili1104, createdTime=Sun Jul 01 02:45:00 CST 2018, time=2018-07-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2044054, encodeId=a7eb2044054bb, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Dec 21 02:45:00 CST 2018, time=2018-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952064, encodeId=a6c919520643f, content=<a href='/topic/show?id=3dbb2346632' target=_blank style='color:#2F92EE;'>#乙酰氨基酚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23466, encryptionId=3dbb2346632, topicName=乙酰氨基酚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Mon Oct 08 21:45:00 CST 2018, time=2018-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011380, encodeId=6e40201138030, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Thu Aug 23 20:45:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321789, encodeId=a5e51321e8925, content=<a href='/topic/show?id=818246618a4' target=_blank style='color:#2F92EE;'>#对乙酰氨基酚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46618, encryptionId=818246618a4, topicName=对乙酰氨基酚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afdf491, createdName=lilili1104, createdTime=Sun Jul 01 02:45:00 CST 2018, time=2018-07-01, status=1, ipAttribution=)]
    2018-08-23 yhy100200
  4. [GetPortalCommentsPageByObjectIdResponse(id=2044054, encodeId=a7eb2044054bb, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Dec 21 02:45:00 CST 2018, time=2018-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952064, encodeId=a6c919520643f, content=<a href='/topic/show?id=3dbb2346632' target=_blank style='color:#2F92EE;'>#乙酰氨基酚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23466, encryptionId=3dbb2346632, topicName=乙酰氨基酚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Mon Oct 08 21:45:00 CST 2018, time=2018-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011380, encodeId=6e40201138030, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Thu Aug 23 20:45:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321789, encodeId=a5e51321e8925, content=<a href='/topic/show?id=818246618a4' target=_blank style='color:#2F92EE;'>#对乙酰氨基酚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46618, encryptionId=818246618a4, topicName=对乙酰氨基酚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afdf491, createdName=lilili1104, createdTime=Sun Jul 01 02:45:00 CST 2018, time=2018-07-01, status=1, ipAttribution=)]

相关资讯

Am J Obstet Gynecol:阿司匹林在预防早产先兆子痫中的获益效应取决于依从性?

2017年12月,发表于《Am J Obstet Gynecol》上的一项研究,考察了依从性对阿司匹林预防早产先兆子痫的获益效果的影响。

Hypertension:sFlt-1/PLGF比值在先兆子痫预测中的作用!

由此可见,sFlt-1/PLGF比值是先兆子痫一个有价值的筛查工具,也有助于决策制定、治疗分层,以及更好的资源分配。

JCEM:JMJD6组蛋白去甲基化酶活性受损影响了先兆子痫VHL基因的表达

大家都知道von Hippel Lindau(VHL)蛋白是细胞缺氧反应的关键执行者,其在先兆子痫这种妊娠中发病率5%-7%的疾病中表现受损。迄今为止,控制VHL基因在人胎盘中表达的机制仍不清楚。近日在JCEM上发表的一篇文章则旨在研究正常妊娠和先兆子痫(一种以胎盘缺氧为特征的病理)的VHL表观遗传调节机制。

Am J Obstet Gynecol:预防先兆子痫 阿司匹林用少了可能对孕妇有害?

女性妊娠如在鬼门前走一遭。据悉,最初的16周胎盘受损与随后先兆子痫、小于胎龄新生儿以及胎盘早剥危险增加相关。阿司匹林长久以来被视为“万能药”,具有抗炎、抗血管生成和抗血小板聚集的特性。此前,有科学家发现预防性使用阿司匹林可以降低先兆子痫和小于胎龄新生儿风险,但对胎盘早剥无显着影响。

Obstet Gynecol:分娩住院期间并发先兆子痫孕妇使用抗高血压药物治疗分析!

由此可见,使用多种抗高血压药物治疗先兆子痫的比例在轻度、中度和严重先兆子痫患者中有所增加。使用抗高血压药物不同医院差异很大,这一趋势与母亲卒中风险降低有关。

Hypertension:父母身高与先兆子痫风险!

由此可见,产妇身高与先兆子痫的相关性不大可能是由于家族、社会经济因素或与身高有关的胎儿基因混杂所致。孕妇身高与先兆子痫之间的相关性值得进一步研究。